[Additional advantages of mexicor used in combined therapy of coronary heat disease and diabetes mellitus of 2nd type].

Abstract

This open prospective randomized 16-week study of combined therapy of coronary heat disease (CHD) and and diabetes mellitus of 2nd type (DM2) with secondary non-alcoholic fatty liver disease (NAFLD) including mexicor was designed to estimate structural and functional liver characteristics. Mexicor was shown to act as a hepatoprotector reducing the frequency of cytolithic syndrome when used together with statins in combined therapy of atherogenic dyslipidemia. It also significantly decreased the number of patients with elevated levels of gamma-glutamyltranspeptidase. These changes suggest favourable prognosis for patients with CHD and DM2 because enhanced activity of this enzyme is believed to be a predictor of high cardiovascular risk. Mexicor promoted combined hypolipidemic effect, reduced the degree of insulin resistance, improved hepatic metabolism, and lowered cardiovascular risks in patients with CHD and DM2.

• Authors: M E Statsenko, S V Turkina, M A Kosivtseva
• Journal: Klinicheskaia meditsina (Klin Med (Mosk)) Vol. 91 Issue 5 Pg. 59-64 ( 2013) ISSN: 0023-2149 [Print] Russia (Federation)
• PMID: 24159791 (Publication Type: English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Pyridines
• ethylmethylhydroxypyridine succinate
• gamma-Glutamyltransferase

Topics

• Aged
• Coronary Disease (blood, drug therapy, epidemiology)
• Diabetes Mellitus, Type 2 (blood, drug therapy, epidemiology)
• Drug Therapy, Combination
• Fatty Liver (blood, drug therapy, epidemiology)
• Female
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Male
• Middle Aged
• Non-alcoholic Fatty Liver Disease
• Prospective Studies
• Pyridines (administration & dosage, pharmacology)
• Treatment Outcome
• gamma-Glutamyltransferase (blood, drug effects)